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Abstract
Background—RCTs demonstrated the newest LTBI regimen, 12 weekly doses of directly 
observed isoniazid and rifapentine (3HP), as efficacious as 9 months of isoniazid (9H) with a 
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greater completion rate (82% versus 69%); however, 3HP has not been assessed in routine health 
care settings.
Methods—Observational cohort of LTBI patients receiving 3HP through 16 US programs was 
used to assess treatment completion, adverse drug reactions (ADRs), and factors associated with 
treatment discontinuation.
Results—Of 3288 patients eligible to complete 3HP, 2867 (87.2%) completed treatment. 
Children 2–17 years had the highest completion rate, 94.5% (155/164). Patients reporting 
homelessness had a completion rate of 81.2% (147/181). In univariable analyses, discontinuation 
was lowest among children (relative risk [RR], 0.44 [95% CI, 0.23–0.85]; P = .014), and highest in 
persons ≥65 years (RR, 1.72 [95% CI, 1.25–2.35] P = .001). In multivariable analyses, 
discontinuation was lowest among contacts of patients with TB disease (adjusted relative risk 
[ARR], 0.68 [95% CI, 0.52–0.89]; P = .005), and students (ARR, 0.45 [95% CI, 0.21–0.98]; P = .
044); highest with incarceration (ARR, 1.43 [95% CI, 1.08–1.89]; P=.013) and homelessness 
(ARR, 1.72 [95% CI, 1.25–2.39]; P = .001). ADRs were reported by 1174 (35.7%) patients, of 
whom 891 (76.0%) completed treatment.
Conclusions—Completion of 3HP in routine health care settings was greater overall than rates 
reported from clinical trials, and greater than historically observed using other regimens among 
reportedly nonadherent populations. Widespread use of 3HP for LTBI treatment could accelerate 
elimination of TB disease in the United States.
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Recommendations for improving prevention and control of tuberculosis (TB) in the United 
States include testing and treatment of persons for latent TB infection (LTBI) [1]. 
Reactivation of LTBI accounts for the majority of TB disease cases; therefore, finding and 
treating LTBI is a key component of the US strategy for TB elimination [2].
Daily self-administered isoniazid (INH) has been the standard therapy for LTBI for ≥50 
years, but its effectiveness is limited by drug toxicity and low rates of treatment completion 
because of the long duration of INH-monotherapy regimens [3]. Adoption of shorter, safer 
regimens is important for increasing treatment completion rates. Randomized controlled 
trials have demonstrated that, compared to 6–9 months of daily INH, the 3HP regimen of 12 
once-weekly doses (3 months) of rifapentine (RPT) plus INH by directly observed therapy 
(DOT) is statistically non-inferior to longer INH regimens for preventing TB and is more 
likely to be completed [4–6].
Although 3HP is recommended as an alternative to daily INH and preferred for patients who 
cannot or are unlikely to complete a longer regimen [2], acceptance and benefits of 3HP that 
have been observed in controlled clinical trials merit confirmation among diverse 
populations and programmatic settings. We sought to measure rates of 3HP treatment 
completion in US non-research settings, determine factors associated with treatment 
discontinuation, and conduct surveillance for adverse drug reactions (ADRs).
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METHODS
Project Design
This post-marketing project was an observational cohort assessment of directly observed 
3HP (weight-adjusted, maximal dose of 900mg each of RPT (P) and INH (H) for patients 
weighting ≥50 kg), implemented through clinics across the United States, including health 
departments, student health centers, correctional facilities, and shelters for persons 
experiencing homelessness. Solicitations for participation were sent to TB controllers in all 
US jurisdictions, and a meeting was convened with interested clinicians and program 
managers to develop standard data collection instruments and assess site-specific needs for 
data collection. Participating project sites agreed programs would share de-identified patient 
data on the basis of their standard practices. Data were observational, dose adherence was 
assessed by DOT, and ADR surveillance was based on patient self-report; the methods were 
designed to be minimally intrusive for participating sites and required only routine practices 
in their programs. Project sites were self-selected and most participating programs used 3HP 
for all LTBI treatment. Local standards and indications for treatment were used at 
participating sites for LTBI diagnosis, and programs developed their own clinical protocols 
and training for 3HP treatment implementation and monitoring. Monitoring of patients who 
took 3HP included a dose and symptom review checklist. A database with 3 nested tiers 
(basic, standard, and comprehensive) for data collection was developed to accommodate 
differing capacities at the volunteer sites. Basic data collection included patient 
demographics, weekly dose and symptom review, and final disposition. Standard data 
collection consisted of basic data collection elements plus selected medical conditions and 
population risk factors for TB, and concomitant medications. Comprehensive data collection 
included all data collected in the standard data collection plus any additional patient 
medications or medical conditions. Standard and comprehensive tier patient care data 
included co-morbid medical conditions, medication use, behavioral risk factors, and 
population risk factors for TB [1]. Co-morbid medical conditions included conditions that 
impair the immune system or involve use of medications that suppress immune response and 
predispose to active TB disease (including diabetes, chronic renal disease, 
immunocompromised (unspecified), hepatitis, chronic lung disease, malnutrition, 
gastrectomy or jejunoileal bypass) and common conditions that involve concomitant use of 
medications that pose potential drug interactions (including hypertension, seizure disorder, 
and mental health disorder). Any medical condition was defined as a patient reporting a co-
morbid medical condition or any other medical condition. Behavioral risk factors were 
alcohol use defined as more than two drinks per day, current or past smoking, intravenous 
drug use, and non-intravenous drug use (IDU). Any substance use risk was defined as a 
patient reporting current or past history of smoking, use of alcohol, IDU, or non-IDU. 
Population risk factors for TB included being a migrant worker, health care worker, or an 
employee or resident in a TB-risk setting (eg, homeless shelter, correctional facility, long-
term care facility).
Six sites were in the basic data collection tier, 4 in the standard tier, and 6 in the 
comprehensive tier. Sites were geographically representative across the United States: 1 in 
the Northeast, 4 in the West, 5 in the Midwest, and 6 in the South. One participating site was 
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federal with 7 health facilities in 6 states. Each site was provided a database shell 
corresponding to its respective specific tier of data collection. Data were collected for 
patients who received ≥1 3HP treatment dose during June 2011 through December 2013, in 
accordance with Centers for Disease Control and Prevention (CDC) recommendations [2].
ADRs were defined as any symptoms reported since receipt of the last 3HP dose [7]. 
Throughout treatment, patients were asked at each weekly DOT visit, or any interim visits or 
calls, to report any ADRs or symptoms experienced since administration of the prior week’s 
medication dose.
Outcome Measures and Associated Factors
Patient care data collected at all sites included demographics, treatment reason, and history 
of homelessness or incarceration anytime during the 12 months before 3HP initiation. 
Reasons for treatment initiation with 3HP were per local policy, not mutually exclusive, and 
included risk for TB exposure or infection, foreign birth in a high prevalence country, and 
persons at high risk for progression to TB disease if infected (eg, persons with human 
immunodeficiency virus [HIV] or other immunosuppressive medical conditions, persons 
taking medications known to increase the risk for disease, and persons with prior 
inadequately treated TB).
Treatment outcomes were completion, temporary discontinuation due to ADRs with 
subsequent continuation and treatment completion, discontinuation due to ADRs (ie, 
provider or patient decision), discontinuation as a result of loss to follow-up, and 
substitution of an alternate regimen. Treatment completion for 3HP was defined as 
documented receipt of 11 or 12 3HP doses, each at least 3 days apart with no more than 5 
doses given within a 28 day period, within 16 weeks of initiating treatment. Patient final 
disposition deemed completion included treatment without interruption, and temporary 
halting with subsequent continuation and completion. Patient final disposition deemed 
discontinuation included stopping due to ADRs, switching to an alternate regimen, and loss 
to follow-up.
Data Management and Statistical Analysis
Patient data were entered into Microsoft Access 2010 databases (Microsoft Corporation, 
Redmond, Washington) developed by CDC. In April 2014, participating sites exported their 
data files to an encrypted, password-protected secure file transport protocol site at CDC. 
After files were downloaded from CDC’s secure site, data for each participating site were 
cleaned; quality and validation checks were run; and incomplete and missing data points for 
individual patients were queried with site collaborators. After review for internal consistency 
and completeness, data from all 16 sites were collated into a single data set. All tiers were 
combined for calculating overall completion rates, and the standard and comprehensive tiers 
were combined for subgroup analyses.
Statistical analyses were performed using SAS® 9.3 (SAS Institute, Cary, North Carolina). 
We described patient characteristics of the entire cohort and calculated discontinuation 
percentages for demographic, treatment indication, medical conditions, and behavioral risk 
factors. We modeled the association of 3HP discontinuation in univariable and multivariable 
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log-binomial regression models by calculating relative risk. Each univariable model looked 
at the association of 3HP discontinuation with potential risk factors individually; age was 
assessed as a continuous variable and as a categorical variable in separate univariable 
models. Relative risk (RR) values, 95% confidence intervals (CIs), and P-values were 
calculated for each potential risk factor. Independent risk factors were tested for significance 
at a level of P≤05.
Two multivariable regression analyses using backward elimination were performed to 
calculate adjusted relative risks (ARRs) using log-binomial regression. Factors considered 
for inclusion in the models were selected a priori and chosen based on subject-domain 
judgement. Age was modeled as a continuous variable in multivariable analyses.
The first model examined the effect of demographic and population factors on 3HP 
treatment discontinuation while controlling for the effect of individual treatment sites for all 
patients starting treatment (n=3288). The second model examined the association of medical 
conditions and behavioral risk factors with 3HP treatment discontinuation among the 
subgroup of patients (n=2389) from standard and comprehensive tier sites, while controlling 
for age. In both multivariable models, associations between covariates and 3HP treatment 
discontinuation were considered significant at P<.05. Treatment reasons, medical conditions, 
and behavioral risk factors were dichotomous variables. Potential interactions were 
hypothesized a priori, interaction terms were entered into the models with all covariates to 
assess their effect. Interaction terms significant at P≤10 were explored [8]. We found no 
evidence of interaction among variables in the model.
Ethics Oversight
CDC determined this assessment of postmarketing experiences was public health practice 
and the project did not involve an investigational intervention, clinical research activities, or 
procedures for which written consent was required. Each participating site obtained ethical 
review and approval for participation in accordance with local requirements.
LTBI treatment was not a US Food and Drug Administration (FDA) approved indication for 
RPT when this assessment began, although 3HP use was recommended by CDC [2]. The 
FDA approved a labeling change (RPT in combination with INH for LTBI) on December 2, 
2014 [9].
RESULTS
Of 3327 patients who received ≥1 dose of 3HP, treatment was stopped for 39 (1.2%) when a 
contraindication developed or was identified. Of those 39 patients, 2 had negative 
QuantiFERON results (lack of LTBI diagnosis), and 37 had contraindications for 3HP: 20 
were contacts of INH-resistant index cases; 14 were women who became pregnant; 2 had 
HIV infection and were taking highly active antiretroviral therapy (HAART); and 1 had TB 
disease. Among the remaining 3288 patients, 421 (12.8%) discontinued treatment (Figure 1). 
Discontinuation rates across the sites ranged from 0.0% to 19.2% (Supplemental Table 1).
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Of the 3288 patients who could have completed treatment, 2928 (89.1%) were aged 18–64 
years and 1994 (60.6%) had been born in the United States. Demographic characteristics of 
the patient cohort are presented in Table 1. Children and adolescents aged 2–17 years had 
the highest treatment completion rates (155 of 164; 94.5%), and patients aged ≥65 years had 
the lowest (154 of 196; 78.6%). Twelve children were aged 2–11 years, and 11 completed 
the regimen. Eight (5.2%) of 155 children aged 12–17 years discontinued treatment: 4 had 
ADRs; 1 was lost to follow-up; 1 refused DOT and requested self-administered therapy but 
did not return for follow-up; and 2 were siblings whose parents disallowed further treatment.
Hispanic patients had the highest rate of treatment completion, and non-Hispanic white 
patients had the lowest (90.8% versus 82.5%). Treatment completion was higher for foreign-
born patients than for US-born patients (90.3% versus 85.2%). Patients with diabetes 
mellitus comprised 7.4% (176 of 2389) of the patient subgroup with medical conditions, and 
83.5% completed treatment.
Approximately one-third (1174 of 3288; 35.7%) of patients reported ≥1 ADRs during 
treatment. Among all patients who reported any reaction temporally associated with taking a 
3HP dose, the most common reactions were nausea, fatigue, sore muscles, headache, fever 
or chills, dizziness, and abdominal pain (Figure 2). Of patients reporting ADRs, 246 (21%) 
discontinued treatment; of those patients, 3HP was most frequently stopped after the third 
dose. Among patients who discontinued treatment (n = 246), the most frequently reported 
reactions were nausea, fever or chills, fatigue, sore muscles, rash or hives, dizziness, and 
headache. Of the 3327 who began 3HP, 26 (0.8%) were hospitalized and 19 (0.6%) patients 
were examined in emergency departments during their treatment course. No deaths or long-
term sequela were reported.
Most patients (2793 of 3288; 85%) completed treatment without interruption. Among 
patients with treatment interruption, 14.9% (74 of 495) temporarily halted but subsequently 
completed (Table 2); 23.2% (115 of 495) discontinued 3HP and were reported to have 
switched to an alternative regimen; 26.5% (131 of 495) of patients discontinued 3HP and 
stopped all LTBI treatment; and 35.4% (175 of 495) of patients were lost to follow-up 
(Supplemental Table 2).
Factors Associated with Treatment Discontinuation
In univariable analysis (Tables 2 and 3, unadjusted RR), the following characteristics were 
significantly associated with increased likelihood of discontinuation of 3HP treatment: aged 
≥65 years, non-Hispanic white race/ethnicity, recent converter (ie, person with baseline 
tuberculin skin test who has ≥10mm increase in induration, or positive interferon-gamma 
release assay (IGRA) with a documented previous negative TB test, within the past 2 years), 
homelessness in the 12 months before treatment, health care worker, or having any 
population risk factor. Patient factors significantly associated with lower likelihood of 
discontinuation of 3HP treatment included the following: aged 2–17 years, being the contact 
of a TB case, foreign birth, or being a student.
In the final multivariable model (Tables 2 and 3, ARR), the following factors were 
associated with significantly greater risk for discontinuing 3HP treatment: having been 
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incarcerated anytime during the 12 months before treatment, or having been homeless 
anytime during the 12 months before treatment. Patients who were significantly less likely to 
discontinue treatment were contacts of a TB case, or students.
Subgroup analyses of 2389 patients with data collected regarding co-morbid medical 
conditions and behavioral risks demonstrated the following factors associated with 
significantly greater risk for discontinuation of 3HP treatment in univariable analysis (Table 
3): hepatitis, chronic lung disease, mental health problems, any medical condition, current or 
past smoking, or any substance use. In multivariable analyses, after controlling for all other 
medical conditions and behavioral factors, patients who were current or past smokers were 
significantly more likely to discontinue 3HP.
DISCUSSION
In this nationwide observational cohort assessment of treatment completion and associated 
ADRs to 3HP for treating LTBI, we determined that completion of the 3HP regimen among 
a diverse patient cohort treated at different types of clinical settings (87.2%) was at least as 
good as that observed in the clinical trial setting (82.1%) and substantively greater than most 
reported rates of completion for the standard 6–9 months of daily self-administered therapy 
with INH (30%–64%) [5–6, 10–13]. CDC recommendations for 3HP [2] were issued on the 
basis of findings from clinical trials; in contrast, this project assessed the frequency of ADR 
and treatment completion outcomes of 3HP offered in routine health care settings. 
Indications for treatment varied across participating sites, with the largest site offering 3HP 
to all persons with LTBI who did not have contraindications.
Approximately two-thirds of patients who took 3HP reported no ADRs during treatment. Of 
those who did report ≥1 reaction, 1 in 5 discontinued treatment. Children, adolescents, and 
younger adults were most likely to complete treatment, but even patients aged ≥65 years had 
higher completion rates for 3HP than observed with standard INH regimens overall [4, 10–
11]. The preferred treatment for children age 2–11 years is 9H because data and experience 
with the 3HP regimen among this age group is limited [2]. However, our data are consistent 
with findings in 1 clinical trial: children age 2–17 years were more likely to complete 
treatment than any other age group and the regimen was well-tolerated [11].
High treatment completion rates were achieved for certain patient groups who historically 
have had low completion rates with INH-only regimens. This assessment included persons 
who were recently or currently homeless or in a correctional facility, persons known to be 
challenging to treat, especially with regimens that require daily dosing [12], and college 
students from high TB prevalence countries who may be lost to follow-up before completion 
of 6–9 months of INH [13]. Although these patient groups have previously been associated 
with higher risk of treatment discontinuation than other patient groups, their completion 
rates were still higher than traditionally seen with 6–9 months of INH. We attribute high 
rates of treatment completion among these populations to the practical advantages of a 
shorter, once-weekly regimen.
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Treatment completion was also high among groups with chronic disease conditions. This is 
important because diabetes mellitus, HIV-infection, and certain other conditions are risk 
factors for progression to TB disease [14]. The majority of participating sites offered 3HP to 
all patients except those for whom 3HP was not recommended (ie, children aged <2 years, 
HIV-infected patients receiving HAART, pregnant women, and patients with presumed INH- 
or rifampin-resistant LTBI). We examined ≥10 medical conditions and determined that only 
persons who were current or past smokers were less likely to complete treatment. Patients 
with diabetes mellitus, HIV-infection not on HAART, or other immunocompromising 
conditions did well with the regimen; these groups did not have more ADRs or adverse 
events reported, and completed treatment at rates similar to other patient groups (Table 1).
One limitation of this project was that it was not a funded study, therefore standardized 
training was not provided to staff. Another limitation was that data capture was tiered for 
selected variables (eg, diabetes mellitus or substance use) and data were not solicited 
uniformly across sites. This project was conducted within routine program operations. As 
such, participating sites and local standards varied in how patients were selected. For 
example, at most sites, 3HP was used for all patients who did not have contraindications; at 
a small number of sites, the regimen was offered to specific patient cohorts (eg, homeless 
persons, correctional population). Programs also varied in how patient histories were taken, 
how dose and symptom review checklists were completed, and how patients were counseled 
regarding reporting of ADRs to medication doses. No additional guidance was provided for 
patient clinical assessment; participating providers might have had varying experience with 
the 3HP regimen and differed in their thresholds for discontinuing therapy when patients 
reported symptoms (eg, abdominal pain) or signs (eg, rash or fever) that might be construed 
as antecedent to a severe adverse event.
This project, reflecting the translation of research and guidelines into routine clinical 
practice, demonstrates that wider adoption of 3HP is possible and should be implemented [2, 
4–6, 14]. Rates of 3HP completion were high for groups with historically low rates of 
completing LTBI regimens such as homeless persons and students. The consistently high 
rates of completion in programmatic settings, in contrast with ≥6 months of INH, hold 
promise of better returns for the investment of treating persons with LTBI to prevent TB 
disease.
The 3HP regimen for LTBI treatment was well tolerated by patients in routine health care 
settings, with high rates of completion and low rates of ADRs resulting in discontinuation, 
among all patient cohorts. Using the new regimen required preparatory and start-up efforts, 
but sites reported long-term efforts after roll-out were comparable with operating procedures 
for other LTBI regimens and had the benefit of higher rates of treatment completion. It is 
possible these findings underestimate the true effect of 3HP and other short course regimens 
on acceptability, uptake, and completion of treatment for LTBI. Expanded use of 3HP could 
facilitate successful treatment of more persons with LTBI to accelerate achieving the goal of 
TB elimination in the United States.
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Figure 1. Profile of Persons with Latent TB Infection Who Took 3HP
aTreatment reason per local policy are dichotomous factors: therefore, n does not equal 3288
bRecent contact of person with contagious TB
cPerson with baseline tuberculin skin test who has ≥10mm increase in induration, or positive 
IGRA with a documented negative TB test, within a 2-year period
Abbreviations: 3HP, a 3-month regimen of isoniazid and rifapentine; HAART, highly active 
antiretroviral treatment; HIV, human immunodeficiency virus; IGRA, interferon-gamma 
release assay; LTBI, latent tuberculosis infection; TB, tuberculosis.
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Figure 2. Number and Percentage of Patients with Medication Reactions After any 3HP dose, 
n=1174a
a
 Patients could report ≥1 reaction, after ≥1 dose
b
 Other symptoms reported by ≥1 patient includes dermatological-related symptoms, gastro-
intestinal symptoms, cough, mental health symptoms, weight loss, blurred vision, flu-like 
symptoms, breathing issues, back pain, gynecologic symptoms, chest discomfort, 
diaphoresis, angioedema, bleeding, palpitations, easy bruising, swelling, neurologic 
symptoms, hypotension/near syncope and syncope, flushing, red eyes, upper respiratory 
infection, genitourinary symptoms, other eye symptoms, black stool, pain, pneumonia, and 
sepsis.
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Table 1
Characteristics Among Patients Started on 3HP
Patient Characteristics (n = 3288) Total Number
No. (%)
Completed 3HP
No. (%)
Sex
Male 1759 (53.5) 1550 (88.1)
Female 1529 (46.5) 1317 (86.1)
Age (yrs.)
2 to 17 164 (5.0) 155 (94.5)
18 to 30 1034 (31.5) 921 (89.1)
31 to 44 953 (29.0) 834 ( 87.5)
45 to 64 941 (28.6) 803 (85.3)
≥ 65 196 (6.0) 154 (78.6)
Race/ethnicity
Hispanic 751 (22.8) 682 (90.8)
Non-Hispanic white 721 (21.9) 595 (82.5)
Non-Hispanic black 1195 (36.3) 1035 (86.6)
Asian 540 (16.4) 481 (89.1)
Other a 81 (2.5) 74 (91.4)
Country of birth
United States 1994 (60.6) 1699 (85.2)
Foreign-born 1294 (39.4) 1168 (90.3)
Treatment reasonb
Contactc 821 (25.0) 751 (91.5)
Converterd 800 (24.3) 670 (83.8)
Corrections during last 12 516 (15.7) 451 (87.4)
Homeless during last 12 181 (5.5) 147 (81.2)
Foreign-born 1294 (39.4) 1168 (90.3)
Refugee 132 (4.0) 113 (85.6)
Health care worker 500 (15.2) 416 (83.2)
Studente 130 (4.0) 123 (94.6)
Employment 211 (6.4) 180 (85.3)
Long-term care resident 47 (1.4) 41 (87.2)
Any population riskf 1534 (46.7) 1315 (85.7)
Medical conditionsg
Diabetes 176 (7.4) 147 (83.5)
Chronic renal disease 30 (1.3) 24 (80.0)
Immunocompromised 91 (3.8) 82 (90.1)
Hepatitis 58 (2.4) 45 (77.6)
Chronic lung disease 78 (3.3) 59 (75.6)
Mental health problems 127 (5.3) 99 (78.0)
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Patient Characteristics (n = 3288) Total Number
No. (%)
Completed 3HP
No. (%)
Hypertension 304 (12.7) 260 (85.5)
Other medical conditionh 572 (23.9) 482 (84.3)
Any medical conditionk 775 (32.4) 649 (83.7)
Behavioral risk factorsf
Alcohol use 211 (8.8) 176 (83.4)
Current or past smoker 534 (22.4) 433 (81.1)
Injection drug use 23 (1.0) 19 (82.6)
Non-Injection drug use 157 (6.6) 129 (82.2)
Any substance use riskm 660 (27.6) 542 (82.1)
aOther race/ethnicity includes American Indian or Alaskan Native, Native Hawaiian or other Pacific Islander, biracial, and unknown.
b
Treatment reasons per local policy are dichotomous factors.
c
Recent contact of person with infectious TB.
d
Person with baseline tuberculin skin test who has ≥10mm increase in induration, or positive interferon-gamma release assay (IGRA) with a 
documented negative TB test, within a 2-year period.
e
Most students were of foreign birth from high prevalence countries, or were contacts or converters; 11 patients not identified as foreign born had 
no treatment indication other than student status.
fAny population risk was defined as being a migrant worker, health care worker, employee or resident in TB-risk setting (eg, homeless shelter or 
correctional facility), or resident in a long-term care facility.
g
Medical conditions and Behavioral risks are dichotomous factors reported for a subgroup of 2389 patients.
hOther medical condition was defined as a patient reporting any medical condition other than diabetes, chronic renal disease, 
immunocompromised, hepatitis, chronic lung disease, mental health problems, or hypertension.
kAny medical condition was defined as a patient reporting diabetes, chronic renal disease, immunocompromised, hepatitis, chronic lung disease, 
mental health problems, hypertension, and any other medical condition.
mAny substance use was defined as a patient reporting current or past history of smoking, use of alcohol, injection drug use, or non-injection drug 
use.
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